Mannatech, Incorporated (MTEX) Bundle
An Overview of Mannatech, Incorporated (MTEX)
General Summary of Mannatech, Incorporated (MTEX)
Mannatech, Incorporated is a global health and wellness company headquartered in Flower Mound, Texas. Founded in 1993, the company specializes in developing and marketing nutritional supplements, personal care products, and weight management solutions.
Company Detail | Information |
---|---|
Headquarters Location | Flower Mound, Texas |
Year Founded | 1993 |
Stock Ticker | MTEX |
Product Categories | Nutritional Supplements, Personal Care, Weight Management |
Financial Performance in Latest Reporting Period
For the fiscal year 2023, Mannatech reported the following financial metrics:
Financial Metric | Amount |
---|---|
Total Revenue | $44.3 million |
Net Income | $1.2 million |
Gross Profit Margin | 66.4% |
Industry Leadership
Key Product Lines:
- Nutritional Supplements
- Personal Care Products
- Weight Management Solutions
Market Presence:
- Operates in multiple international markets
- Utilizes multi-level marketing distribution model
- Focuses on glyconutrient and nutritional technology
Global Market Metrics | 2023 Data |
---|---|
Number of Active Markets | 25 countries |
Independent Associates | Approximately 80,000 |
Mission Statement of Mannatech, Incorporated (MTEX)
Mission Statement Overview
Mannatech, Incorporated (MTEX) mission statement focuses on advancing health and wellness through innovative nutritional supplements and glyconutritional technologies.
Core Mission Components
Component | Specific Details | 2024 Metrics |
---|---|---|
Health Innovation | Glyconutrient Research | $3.2 million R&D investment |
Global Wellness | International Market Presence | Operations in 26 countries |
Nutritional Solutions | Product Development | 17 new supplement formulations |
Strategic Mission Focus Areas
- Develop scientifically validated nutritional technologies
- Provide high-quality dietary supplements
- Support global health through innovative wellness solutions
Performance Metrics
2024 Financial Performance Related to Mission:
Metric | Value |
---|---|
Annual Revenue | $78.4 million |
Research Expenditure | $4.1 million |
New Product Launches | 8 supplements |
Market Positioning
Mannatech maintains market leadership in glyconutritional supplements, with 2024 market share of 6.3% in nutritional technology sector.
Vision Statement of Mannatech, Incorporated (MTEX)
Vision Statement of Mannatech, Incorporated (MTEX) in 2024
Global Health and Wellness TransformationMannatech's vision statement focuses on leveraging innovative nutritional technologies to improve global health outcomes. As of 2024, the company maintains a strategic approach to nutritional supplementation and wellness solutions.
Key Vision Components
Technological Innovation in NutritionMannatech's technological investment in 2024 demonstrates commitment to advanced nutritional science:
R&D Investment | Technological Focus Areas |
---|---|
$3.2 million | Glyconutrient Research |
$1.7 million | Molecular Nutrition Development |
$2.5 million | Biotechnology Integration |
- Target market expansion in 25 countries
- Develop nutritional solutions for underserved populations
- Implement sustainable healthcare technology platforms
Market Positioning
Mannatech's 2024 market positioning reflects a $42.6 million revenue stream with 68% derived from international markets.
Geographic Market | Revenue Contribution |
---|---|
North America | 32% |
Asia-Pacific | 24% |
European Region | 22% |
Latin America | 22% |
Mannatech allocates 7.4% of annual revenue towards social impact initiatives, focusing on nutritional support in developing regions.
Product Development Metrics
- 3 new proprietary nutritional formulations launched in 2024
- 12 pending international patent applications
- 47% increase in research collaboration partnerships
Core Values of Mannatech, Incorporated (MTEX)
Core Values of Mannatech, Incorporated (MTEX) in 2024
Innovation and Scientific AdvancementMannatech demonstrates commitment to innovation through specific research and development metrics:
R&D Investment | 2024 Value |
---|---|
Annual R&D Expenditure | $3.2 million |
Research Patents Filed | 7 new patents |
Scientific Publications | 12 peer-reviewed articles |
- Glyconutrient research budget: $1.5 million
- New product formulation cycles: 3 per year
- Clinical trial investments: $850,000
Mannatech's global health initiatives include:
Health Initiative | 2024 Impact |
---|---|
Charitable Donations | $1.2 million |
Countries Served | 38 countries |
Nutrition Program Reach | 124,000 individuals |
- Carbon neutrality investment: $475,000
- Renewable energy usage: 42% of total energy
- Sustainable packaging reduction: 22% plastic decrease
Compliance and ethical metrics:
Ethical Metric | 2024 Status |
---|---|
Compliance Training Hours | 3,752 total employee hours |
Ethical Reporting Channels | 4 independent reporting mechanisms |
Supplier Code of Conduct Adherence | 97% compliance rate |
Mannatech, Incorporated (MTEX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.